Myasthenia Gravis and Cosmetic Surgery: The Droopy Eyelid That Is Not Aging, Why Botox Carries a Warning, Ptosis Repair, Anesthesia, Steroids, and the Thymectomy Scar

The patient is 41 and wants an upper eyelid lift. Myasthenia gravis and cosmetic surgery are not on her mind; tired eyes are. Her photos from the morning look fine. Her photos from the end of a workday show the left lid sitting low over the iris, the brow hiked up to compensate, and a face that looks, in her words, exhausted and sad. She mentions in passing that she sometimes sees double while driving home and that it goes away if she closes one eye. A medical spa offered toxin to lift her brows. A surgeon booked her for a blepharoplasty. Nobody asked her to look up at the ceiling for a full minute and watched the lid slowly sink.

That minute is the whole consultation. Myasthenia gravis is an autoimmune disease of the junction between nerve and muscle, and its signature is weakness that gets worse with use and better with rest. The eyelid muscles are among its favorite early targets, which means the disease frequently walks into cosmetic offices disguised as aging. What follows is how to recognize it, why the toxin label singles it out, when eyelid surgery is reasonable and how it changes, what an anesthesia team has to plan for, and how steroids, newer immune drugs, and a thymectomy scar fit into elective surgery for patients who already know they have it.

Myasthenia gravis and cosmetic surgery: the droopy eyelid that is not aging

The short answer: ptosis that changes through the day, worsens with sustained upward gaze, shifts from one eye to the other, or comes with double vision suggests myasthenia gravis, and it needs a neurologic diagnosis before any cosmetic eyelid or toxin treatment.

In myasthenia gravis, the immune system makes antibodies that interfere with the receptors muscles use to hear the nerve's signal. The most common target is the acetylcholine receptor; a smaller group of patients has antibodies against a related protein called MuSK, and some have no antibody that current tests detect. The result is the same: each repeated signal gets through a little less reliably, so muscles that work hard and continuously tire first. The muscles that hold the eyelids open and aim the eyes are small, busy, and especially vulnerable, and the Myasthenia Gravis Foundation of America notes that eye symptoms are the first sign in a large share of patients. Some never progress beyond the eyes (ocular myasthenia). Many go on to develop generalized weakness, most often within the first couple of years.

The disease has a bimodal pattern that overlaps neatly with cosmetic demographics: it tends to appear in women in their twenties through forties and in men later in life. It can be mild for years. It is easy to miss because it rarely looks dramatic in a single photograph.

Features that separate myasthenic ptosis from the ordinary kind:

• Variability. Aging ptosis from a stretched levator tendon is steady. Myasthenic ptosis is worse in the evening, after reading or screen time, in heat, and during illness, and better after sleep.
• Fatigue on demand. Sustained upgaze for a minute or so makes a myasthenic lid sink visibly. Cogan's lid twitch, a brief overshoot of the lid when the eyes return from looking down to straight ahead, is another bedside sign.
• Switching sides. Ptosis that moves from one eye to the other over weeks is a strong clue.
• Double vision. Weak eye muscles drift out of alignment, and the double vision often disappears when one eye is covered.
• The ice test. A cold pack held over the closed lid for a couple of minutes often improves myasthenic ptosis measurably, because cooling helps the junction work. It is a screening clue, not a diagnosis.

The diagnosis itself belongs to a neurologist or neuro-ophthalmologist and usually rests on antibody blood tests and, when those are negative, specialized nerve conduction testing such as single-fiber electromyography. A chest CT or MRI often follows, because a subset of patients has a thymoma, a tumor of the thymus gland that sits behind the breastbone. The piece on eyelid ptosis versus blepharoplasty lists fluctuating ptosis among the findings that should stop a cosmetic conversation, and the piece on hooded eyes versus brow ptosis explains how a hiked compensating brow can make a lid problem look like a skin problem. Both apply here with more force: taking skin off a lid that droops because its muscle is failing does not lift the lid, and it can leave the eye less protected.

The face shows the disease in other ways that bring patients to cosmetic offices. Weakness of the muscles around the mouth can flatten a smile into what neurologists call the myasthenic snarl, where the corners pull sideways instead of up. The jaw can tire during chewing, and the voice can turn nasal late in the day. A patient who asks for fillers or a lip flip because "my smile looks different now" deserves the same question as the patient with the sinking lid: is it different in the morning?

Botox, fillers, and a warning written for this disease

The short answer: botulinum toxin works by blocking the same nerve-to-muscle junction that myasthenia gravis already weakens, so the FDA labeling for every cosmetic neurotoxin warns that people with neuromuscular junction disorders face a higher risk of serious effects, and most clinicians treat known myasthenia as a reason to avoid cosmetic toxin.

Botulinum toxin blocks the release of acetylcholine from the nerve ending. Myasthenia blocks the muscle's ability to receive it. Put the two together and the margin of safety shrinks from both sides. The prescribing information for the cosmetic toxins sold in the United States carries a warning that patients with neuromuscular disorders, naming myasthenia gravis and Lambert-Eaton syndrome, may be at increased risk of clinically significant effects, including marked ptosis, double vision, difficulty swallowing, and breathing problems, even at typical doses. The boxed warning about toxin effects spreading beyond the injection site sits on top of that.

There is a second problem, and it is the one that matters for patients who do not yet know they have the disease. The medical literature contains case reports of cosmetic toxin unmasking previously undiagnosed myasthenia: a patient receives a routine forehead or crow's-feet treatment and days later develops ptosis, double vision, or trouble swallowing far out of proportion to the dose. In some of those reports the toxin did not cause the disease; it revealed a junction that was already running close to failure. That is one more reason a careful injector asks about variable eyelid droop, double vision, and fatigue before the first treatment, and why the piece on Botox brow lifts cautions against toxin near the brows in anyone whose lids already sit low.

What this means in practice:

• Known myasthenia. Cosmetic toxin is generally avoided. A small number of neurologists and oculoplastic surgeons have treated well-controlled patients with very low doses for medical indications, with the neurologist's agreement, but cosmetic wrinkle relaxation rarely justifies the trade. The lip flip piece already lists myasthenia as a reason for caution, and the logic extends to masseter toxin and the Nefertiti lift, where a swallowing or neck-strength problem would be far more serious than a heavy brow.
• A bad reaction to toxin. Ptosis, double vision, or swallowing trouble after an ordinary dose should prompt evaluation, not just reassurance that it will wear off. The piece on why Botox stops working covers the opposite problem; this is the case where it works far too well.
• Fillers. Hyaluronic acid filler does not act on the neuromuscular junction, and myasthenia is not a contraindication in itself. The cautions are indirect: patients on immunosuppressants carry more infection risk, steroid-thinned skin bruises easily, and filler placed to "fix" a myasthenic smile treats the wrong problem.

"Toxin blocks the signal from the nerve. Myasthenia blocks the muscle from hearing it. A patient with both is running the same circuit with two breakers already tripped."

Ptosis repair and eyelid surgery: stability first, then a conservative lift

The short answer: eyelid surgery is possible in myasthenia gravis, but only after the disease has been stable on treatment for a sustained period, usually with a smaller lift, often a different technique, and an explicit plan for double vision and dry eye.

Most myasthenic ptosis improves with medical treatment, and that is the first answer. Pyridostigmine, the standard symptomatic drug, strengthens the signal at the junction and often lifts the lids within days; steroids and other immune treatments, covered below, frequently do more. Surgery enters the conversation for a narrower group: patients, often with ocular myasthenia, whose ptosis persists despite good treatment and whose disease has been stable long enough that the lid position is predictable. Oculoplastic and neuro-ophthalmology literature describes ptosis repair in that setting with reasonable results, and consistently emphasizes waiting for stability.

Why caution persists even then:

• A moving target. Lid height in myasthenia can change with a flare, a medication change, an infection, or stress. A lift measured on a good day may be too much on a bad one and too little after a relapse. Many surgeons aim deliberately low.
• Technique choice. Standard ptosis repair tightens or advances the levator muscle, which depends on that muscle having reliable strength. When levator function is poor or fluctuates, some surgeons prefer a frontalis sling, which suspends the lid from the forehead muscle so the patient can lift it with the brow. Others use small, adjustable levator procedures. The choice depends on measured muscle function, not on preference.
• Eye closure. Myasthenia weakens the orbicularis, the muscle that closes the eye, as well as the levator. A lid that is lifted when the closing muscle is weak may not shut fully during sleep, which exposes the cornea. That is the same failure pathway behind the piece on dry eye after eyelid surgery, and it argues for a tear film assessment, lubrication plans, and a modest lift.
• Double vision unmasked. A droopy lid can block one eye's view and hide an eye-muscle imbalance. Lift the lid and the patient may suddenly see double all day. Prisms, patching, or strabismus surgery may be needed, and the patient should hear that possibility before the operation, not after.

Cosmetic blepharoplasty, meaning removal of excess skin and fat for appearance, is a separate question. In a patient with well-controlled disease, normal eye closure, and a stable lid position, a conservative skin excision may be reasonable; the piece on blepharoplasty for sagging skin and under-eye bags covers the basic operation. Lower lid surgery deserves extra care because a weak orbicularis is one of the conditions that predispose to lower lid retraction, the problem examined in the piece on revision blepharoplasty. Myasthenia also travels with autoimmune thyroid disease more often than chance would predict, and a patient with both may have lid retraction from one disease and ptosis from the other; the piece on thyroid eye disease and eyelid surgery explains why that eye needs a specialist's map before anyone cuts.

Anesthesia and the medication list: what the team must plan for

The short answer: myasthenia gravis changes how patients respond to muscle relaxants, makes many common drugs risky, and raises the chance of breathing trouble after surgery, so elective cosmetic surgery belongs in an accredited facility with a neurologist's input and an anesthesia plan written for this disease.

Muscle relaxants are where myasthenia most directly collides with general anesthesia. Patients are typically very sensitive to the nondepolarizing relaxants used to place a breathing tube and keep muscles still, and relatively resistant to succinylcholine, the fast-acting depolarizing drug. Anesthesiologists respond by avoiding relaxants when possible, using reduced doses with careful monitoring of twitch strength when they are needed, and choosing drugs that can be fully reversed; sugammadex, which binds rocuronium directly, has changed that calculation for many teams. The piece on anesthesia choice and the operative plan explains the broader trade-offs between local, sedation, and general anesthesia. For a myasthenic patient, the right answer depends on the operation and on how well the disease is controlled, and heavy sedation is not automatically safer than a controlled general anesthetic, because sedatives and opioids also depress breathing in someone with weak respiratory muscles.

The rest of the medication list matters just as much:

• Antibiotics. Several classes can worsen myasthenia. Fluoroquinolones such as ciprofloxacin and levofloxacin carry an FDA boxed warning for exacerbating it, and aminoglycosides and macrolides such as azithromycin are also on the caution lists that neurologists hand out. The piece on antibiotics after cosmetic surgery covers the usual choices; this patient's surgeon should check the prescription against the neurologist's list.
• Magnesium. Intravenous magnesium, sometimes used for other purposes around surgery, can weaken neuromuscular transmission and is generally avoided.
• Blood pressure drugs. Beta-blockers can worsen myasthenic weakness in some patients, a point to coordinate with the piece on blood pressure medications before cosmetic surgery.
• Pain control. Opioids and benzodiazepines depress breathing, which is why the opioid-sparing recovery piece is especially relevant, provided its alternatives are themselves checked against the caution list.
• Local anesthetics. Ester-type local anesthetics are broken down by an enzyme that pyridostigmine inhibits, so their effects can be prolonged. Large doses of any local anesthetic, as in extensive tumescent liposuction, can affect neuromuscular function, a reason to keep volumes conservative and stage large procedures.
• Pyridostigmine itself. Patients usually continue it around surgery, but the exact morning dose and the plan if they cannot swallow afterward are decisions for the neurologist and anesthesiologist together.

The serious postoperative risk is myasthenic crisis, a flare in which breathing or swallowing muscles weaken enough to require a ventilator. Surgery, infection, pain, poor sleep, and several of the drugs above are recognized triggers. Patients with generalized disease, a history of crisis, weak bulbar muscles (swallowing and speech), or poor breathing test results are at highest risk, and neurologists sometimes give intravenous immunoglobulin or plasma exchange before surgery to bring the disease under tighter control first. Breathing tests such as forced vital capacity give the team a baseline. The overlap with sleep apnea before cosmetic surgery is real: both turn the first postoperative night into the dangerous one.

That combination argues strongly against an office suite without overnight monitoring for anything beyond small procedures under local anesthesia. The piece on outpatient facility accreditation and the piece on hospital privileges describe what to ask; for a patient with generalized myasthenia, a hospital or hospital-affiliated surgery center that can admit and ventilate is the reasonable standard. Hoarseness and a weak swallow after intubation can also be harder to read in this group, and the piece on sore throat and hoarseness after the breathing tube explains what is ordinary. Long operations that combine several procedures add anesthetic time, immobility, and blood clot risk, and staging them is usually the wiser plan.

Steroids, immune drugs, and the thymectomy scar

The short answer: the treatments that control myasthenia, especially long-term steroids, newer immune therapies, and thymectomy, shape cosmetic surgery as much as the disease does, through wound healing, infection risk, visible steroid changes, and a chest scar that tends to thicken.

Prednisone remains a mainstay for many patients, and its cosmetic footprint is familiar: a rounder face, weight gain around the trunk, thin skin that bruises and tears, stretch marks, and slower wound healing. Two points are specific to myasthenia. Starting or sharply increasing steroids can temporarily worsen weakness before it improves, which is why neurologists often begin low and build up; nobody should plan surgery during that window. And patients on long-term steroids may need stress dosing around an operation because their own adrenal glands have been suppressed. The piece on steroids for swelling after plastic surgery covers the short-course version; this is the long-course one, and it calls for coordination, not improvisation. Patients who want to address steroid-related facial fullness should know that it often settles as the dose comes down, which argues for waiting rather than operating on a face that is still changing.

The steroid-sparing and newer drugs bring their own planning questions, and the general framework is laid out in the piece on cosmetic surgery with autoimmune disease:

• Azathioprine and mycophenolate suppress the immune system broadly and modestly raise infection risk. Whether to continue them through elective surgery is the neurologist's call, and stopping them abruptly risks a flare.
• Rituximab, used particularly in MuSK-positive disease, depletes antibody-making B cells for months; timing elective surgery in relation to infusions is a common question.
• Complement inhibitors, a class of infused or injected drugs used for generalized antibody-positive disease, carry an FDA boxed warning for serious meningococcal infections and require vaccination. A fever after surgery in a patient on one of these drugs is not a routine call.
• FcRn blockers, the newest class, lower antibody levels in cycles; neurologists often prefer elective surgery at a point in the cycle when the disease is quiet.
• IVIG and plasma exchange are used for flares and sometimes as preparation before surgery.

Thymectomy is the other treatment with a cosmetic consequence. The randomized MGTX trial, published in the New England Journal of Medicine in 2016, showed that removing the thymus improved outcomes in patients with generalized, acetylcholine receptor antibody-positive myasthenia without a thymoma, and thymectomy is standard for anyone with a thymoma. Many operations are now done through small incisions on the side of the chest using video or robotic techniques. Others still use a median sternotomy, a vertical incision down the breastbone. The skin over the sternum is one of the body's most reliable places for hypertrophic scars and keloids, and patients sometimes ask about revision. The piece on scar care after plastic surgery covers the options, from silicone and steroid injection to surgical revision, with the usual caution that a keloid cut out without follow-up treatment tends to return larger. Breast augmentation or reduction after a sternotomy is generally feasible, but the surgeon should know where the incision, wires, and any chest wall tenderness sit.

The overlap with other neurologic conditions is instructive. The piece on multiple sclerosis and cosmetic surgery describes a similar principle: plan around periods of stability, involve the neurologist early, and treat the first postoperative days as the period of greatest risk. The piece on Bell's palsy and synkinesis shows how differently a facial nerve problem behaves from a junction problem, which is one reason "facial weakness" is never a single diagnosis.

The honest summary

Myasthenia gravis is a disease that frequently introduces itself in the eyelids, at the age when people start booking eyelid consultations. A lid that droops more at night than in the morning, sinks during a minute of looking up, shifts from side to side, or comes with double vision is not a skin problem, and blepharoplasty or brow toxin will not fix it. Botulinum toxin and myasthenia act on the same junction from opposite sides, which is why the FDA labeling warns about it and why most clinicians avoid cosmetic toxin in known disease. A bad reaction to an ordinary dose deserves a neurologic question rather than a shrug.

For patients who already carry the diagnosis, cosmetic surgery is not off the table, but it moves on the disease's schedule. Eyelid surgery waits for stability and usually aims low. General anesthesia needs a team that knows the muscle relaxant rules, a medication list checked against the caution lists for antibiotics, magnesium, and beta-blockers, and a facility that can monitor breathing overnight. Steroids, immune drugs, and a thymectomy scar shape timing and healing as much as the disease itself. Bring the neurologist's letter to the consultation, and if the surgeon does not ask for it, a second consultation is a reasonable step. The right first question about a droopy eyelid is not how much skin to remove. It is whether the lid looks the same at nine in the evening as it does at nine in the morning.